Companies Dominating the Optic Neuritis Treatment Landscape
- Santen Pharmaceutical Co., Ltd.
- Company Overview
- Business Strategy
- Key Product Offerings
- Financial Performance
- Key Performance Indicators
- Risk Analysis
- Recent Development
- Regional Presence
- SWOT Analysis
- Mallinckrodt plc
- AbbVie Inc.
- Novartis AG
- Sanofi-aventis Groupe
- AdvoCare International
- Hikma Pharmaceuticals PLC
- Henry Schein, Inc.
- Fresenius Kabi USA
- Pfizer Inc.
Browse key industry insights with market data tables & charts from the report:
Frequently Asked Questions (FAQ)
In the year 2025, the industry size of optic neuritis treatment is estimated at USD 267.55 million.
The optic neuritis treatment market size was over USD 245.1 million in 2024 and is anticipated to cross USD 497.71 million by 2037, witnessing more than 5.6% CAGR during the forecast period i.e., between 2025-2037. Rising incidences of bacterial infections across the globe and the significant increment in global geriatric population will boost the market growth.
North America industry is likely to hold largest revenue share of 35% by 2037, impelled by higher adoption of steroids in the region.
The major players in the market are Santen Pharmaceutical Co., Ltd., Mallinckrodt plc, AbbVie Inc., Novartis AG, Sanofi-aventis Groupe, AdvoCare International, Hikma Pharmaceuticals PLC, Henry Schein, Inc., Fresenius Kabi USA, Pfizer Inc.
